

10/581903

AP3 Rec'd PCT/PTO 07 JUN 2005

Docket No.: 21910-00016-US2
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Mario Mellado et al.

Application No.: National Phase of PCT/ES04/000188

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: PREVENTION OF HIV-1 INFECTION BY
INHIBITION OF RHO-MEDIATED
REORGANIZATION AND/OR CONTENT
ALTERATION OF CELL MEMBRANE
RAFT

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Copies of the references on the PTO/SB/08 are not provided.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this

10/581903

AP3 Rec'd PCT/PTO 07 JUN 2006

Application No.: National Phase of PCT/ES04/000188

Docket No.: 21910-00016-US2

Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0185, under Order No. 21910-00016-US2. A duplicate copy of this paper is enclosed.

Dated: June 7, 2006

Respectfully submitted,

By 

Burton A. Amernick

Registration No.: 24,852

CONNOLLY BOVE LODGE & HUTZ LLP

1990 M Street, N.W., Suite 800

Washington, DC 20036

(202) 331-7111

(202) 293-6229 (Fax)

Attorney for Applicant

10/581903

AP3 Rec'd PCT/PTO 07 JUN 2008

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	Not Yet Assigned	
			Filing Date	Concurrently Herewith	
			First Named Inventor	Mario Mellado	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	21910-00016-US2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-2002142940-A1	10-03-2002	Scott et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-00/47196-A	08-17-2000	Hollis Eden Pharmaceuticals In		
	BB	WO-93/24660-A	12-09-1993	Glenn Jeffrey S; Univ California		
	BC	WO-00/02558-A	01-20-2000	Lonchamp Marie Odile; Prevost Gregoire; SOD Conseils Rech Appli		
	BD	WO-03/039477-A	05-15-2003	Schmaljohn Alan L; Bavari Sina		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	Maziere J.C. et al., "Lovastatin Inhibits HIV-1 Expression in H9 Human T Lymphocytes Cultured in Cholesterol-Poor Medium" Biomedicine and Pharmacotherapy, Isevier, Paris, FR, vol. 48, no. 2, 1994, pp. 63-67		
	CB	Nalbone Gilles et al., "[Pleiotropic effects of statins: Implications in the treatment of cardiovascular diseases.]" M-S (Medecine Sciences), vol. 18, no. 12, 12-2002, pp. 1257-1265		
	CC	Manes Santos et al., "Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection" EMBO Reports, vol. 1, no. 2, 8-2000, pp. 190-196		
	CD	Gower T.L. et al., "Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro," Antimicrobial Agents and Chemotherapy, 4-2001, vol. 45, no. 4, pp. 1231-1237		
	CE	Argyris E. G. et al., "Human Immunodeficiency Virus Type 1 Enters Primary Human Brain Microvascular Endothelial Cells by a Mechanism Involving Cell Surface Proteoglycans Independent of Lipid Rafts," Journal of Virology 2003 US, vol. 77, no. 22, 2003, pp. 12140-12151		
	CF	Del Real G. et al., "Statins inhibit HIB-1 infection by down-regulating Rho activity," Journal of Experimental Medicine, 8-16-2004 US, vol. 200, no. 4, 8-16-2004, pp. 541-547		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

469235